Skip to main content

Anti-Rheumatic Rx

Treatment of MIS-C COVID in Kids

Jun 21, 2021

The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular

Read Article

Tofacitinib Efficacy in COVID-19 Pneumonia

Jun 21, 2021

NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.



This multicenter trial was conducted in Brazil. A total of 289 hospitalized

Read Article

Do B-cell targeted therapies still have a place for the treatment of Sjogren’s?

B-cells play a major role in the pathogenesis of primary Sjogren’s syndrome (pSS) through antibody-dependent and antibody-independent functions, as well as evident by progression to B-cell malignancies/lymphoma. Hence, targeting B-cell is attractive. Despite efficacy of B-cell depleting therapy

Read Article

EULAR 2021 – Day 4 Report

Jun 17, 2021

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article

Problems at the FDA

Jun 16, 2021

"While the Food and Drug Administration decision on new drugs usually follows the recommendations of the advisory committee..."; this oft used proviso is used to either indicate a pending FDA decision or an FDA decision that is contrary to the recommendation of the advisory committee convened

Read Article
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response. Read more. https://t.co/0d1bxBlUS0 https://t.co/OZzJKwNJ4i
Dr. John Cush @RheumNow( View Tweet )
Jun 15, 2021

Psoriatic arthritis mortality & morbidities

Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. The current study of Tillett et al (OP0231) assessed comorbidities and patient characteristics comparing

Read Article

Current approach to lupus and pregnancy

Jun 14, 2021

All of us are extremely cautious with lupus patients when it comes to pregnancy. Presentation 6888 (Common issues in pregnancy management in lupus and anti-phospholipid syndrome by Dr. Rebecca Fischer-Betz) was an excellent overview of our current approach to lupus and pregnancy. 

Read Article

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

Q-DAPSA for Measuring Disease Activity in PsA

Jun 10, 2021

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

Read Article
Video: Combination DMARD for Lupus Nephritis: Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021 https://t.co/RGVZ6jukYy https://t.co/PTjSOfM7YQ
Dr. John Cush @RheumNow( View Tweet )
Jun 09, 2021
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021

Lessons learned in SLE

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351). Markers of pathways

Read Article
#EULAR2021 - Day 3 Report https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021

EULAR 2021 - Day 3 Report

Jun 07, 2021

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read Article

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article

Israel provides COVID vaccine answers for rheumatic disease patients

Jun 07, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has

Read Article
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 ) Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021. https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
Dr. John Cush @RheumNow( View Tweet )
Jun 07, 2021
Excellent talk on SLE, APS abs pregancy ⭐️pregnancy counseling is important ⭐️aspirin 81mg in all pregnant SLE pts ⭐️do not discontinue HCQ ⭐️stable LN - can switch MMF to AZA Abs#6888 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 06, 2021
On choosing an agent for MTX-IR RA: "(at the end of talk) My short answer could have been... there's no right or wrong. It's still one of the dilemmas we have in the treatment of RA: choosing the right drug for the right patient" - @DanielAletaha #EULAR2021 @RheumNow https://t.co/C45ey1SrA1
David Liew @drdavidliew( View Tweet )
Jun 06, 2021
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow

Paul Studenic @Stiddyo( View Tweet )

Jun 06, 2021
Results: MTX vs. PBO ✅Difference in least-squares mean ΔeGFR 0.93 mL/min/1.73m2 (p<0.001) ✅HR for kidney AE on safety labs: 0.73 (0.59-0.91) ✔️HR for kidney AE clinical events: 0.87 (0.56-1.36) ✔️4 vs. 8 severe kidney AEs (HR 0.50, 0.15-1.64)

Jeffrey Sparks MD MMSc @jeffsparks( View Tweet )

Jun 05, 2021
HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 05, 2021
🤜MTX safe from kidney perspective if baseline CrCl 40+ 🤜Potential for immunomodulation to prevent/slow progression to CKD? Deserves dedicated studies @Nephro_Sparks

Jeffrey Sparks MD MMSc @jeffsparks( View Tweet )

Jun 05, 2021
Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 05, 2021
×